Novo is set to exit the cancer drug developer in a purchase by another of its shareholders, Boehringer Ingelheim, that could reach $1.43bn.
Pharmaceutical firm Boehringer Ingelheim has agreed to acquire the shares in Switzerland-based cancer immunotherapy developer NBE-Therapeutics it does not already hold, in a deal that could reach €1.18bn ($1.43bn) in size.
The shares will be bought from investment group PPF Group and the rest of the company’s shareholders, which likely include pharmaceutical company Novo. The full figure includes potential clinical and regulatory milestone payments.
NBE is developing antibody-drug conjugate (ADC) therapies to treat cancer and its lead product candidate, NBE-002,…
